These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37196645)

  • 1. Absorbed dose coefficients for adult thyroid cancer patients undergoing radioiodine therapy.
    Kwon TE; Pasqual E; Kitahara CM; Lee C
    J Radiol Prot; 2023 May; 43(2):. PubMed ID: 37196645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in
    Plyku D; Hobbs RF; Huang K; Atkins F; Garcia C; Sgouros G; Van Nostrand D
    J Nucl Med; 2017 Jul; 58(7):1146-1154. PubMed ID: 28104741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
    Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
    J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absorbed dose coefficients for pediatric differentiated thyroid cancer patients undergoing radioiodine therapy.
    Kwon TE; Kitahara CM; Lee C
    J Radiol Prot; 2024 Feb; 44(1):. PubMed ID: 38232407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin.
    Klubo-Gwiezdzinska J; Burman KD; Van Nostrand D; Mete M; Jonklaas J; Wartofsky L
    Thyroid; 2012 Mar; 22(3):310-7. PubMed ID: 22313411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer.
    Ma C; Xie J; Liu W; Wang G; Zuo S; Wang X; Wu F
    Cochrane Database Syst Rev; 2010 Nov; 2010(11):CD008302. PubMed ID: 21069705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Low-dose and High-dose Radioactive Iodine Ablation With rhTSH in Korean Patients With Differentiated Thyroid Carcinoma: The First Report in Nonwestern Countries.
    Joung JY; Choi JH; Cho YY; Kim NK; Sohn SY; Kim SW; Chung JH
    Am J Clin Oncol; 2016 Aug; 39(4):374-8. PubMed ID: 24732812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant or endogenous thyroid-stimulating hormone for radioactive iodine therapy in thyroid cancer: state of knowledge and current controversies.
    Coerts HI; de Keizer B; Marlowe RJ; Verburg FA
    Eur J Endocrinol; 2023 Feb; 188(2):. PubMed ID: 36655579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH.
    Tala H; Robbins R; Fagin JA; Larson SM; Tuttle RM
    J Clin Endocrinol Metab; 2011 Jul; 96(7):2105-11. PubMed ID: 21565788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal.
    Tuttle RM; Brokhin M; Omry G; Martorella AJ; Larson SM; Grewal RK; Fleisher M; Robbins RJ
    J Nucl Med; 2008 May; 49(5):764-70. PubMed ID: 18413378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function.
    Tuttle RM; Lopez N; Leboeuf R; Minkowitz SM; Grewal R; Brokhin M; Omry G; Larson S
    Thyroid; 2010 Mar; 20(3):257-63. PubMed ID: 20187781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal.
    Taïeb D; Sebag F; Farman-Ara B; Portal T; Baumstarck-Barrau K; Fortanier C; Bourrelly M; Mancini J; De Micco C; Auquier P; Conte-Devolx B; Henry JF; Mundler O
    J Clin Endocrinol Metab; 2010 Jul; 95(7):3283-90. PubMed ID: 20392868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer.
    Freudenberg LS; Frömke C; Petrich T; Marlowe RJ; Koska WW; Brandau W; Eising EG; Knust EJ; Bockisch A; Jentzen W
    Exp Clin Endocrinol Diabetes; 2010 Jul; 118(7):393-9. PubMed ID: 19856257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential use of recombinant human thyrotropin in the treatment of distant metastases in patients with differentiated thyroid cancer.
    Klubo-Gwiezdzinska J; Burman KD; Van Nostrand D; Mete M; Jonklaas J; Wartofsky L
    Endocr Pract; 2013; 19(1):139-48. PubMed ID: 23186979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of recombinant human thyroid stimulating hormone on long-term salivary gland dysfunction in thyroid cancer patients treated with radioactive iodine. A systematic review.
    Sunavala-Dossabhoy G; Petti S
    Oral Oncol; 2023 Jan; 136():106280. PubMed ID: 36525783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal preparation for radioiodine ablation in differentiated thyroid cancer in children, adolescents and young adults.
    Schumm MA; Pyo HQ; Kim J; Tseng CH; Yeh MW; Leung AM; Chiu HK
    Clin Endocrinol (Oxf); 2021 Aug; 95(2):344-353. PubMed ID: 33704813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of TSH stimulation protocols on adequacy of low-iodine diet for radioiodine administration.
    Lee H; Paeng JC; Choi H; Cho SW; Park YJ; Park DJ; Lee YA; Chung JK; Kang KW; Cheon GJ
    PLoS One; 2021; 16(9):e0256727. PubMed ID: 34492048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human thyrotropin versus thyroid hormone withdrawal preparation for radioiodine ablation in differentiated thyroid cancer: Experience in a South Taiwanese medical center.
    Tsai JR; Wu ST; Chi SY; Yang YT; Chan YC; Lim LS; Chiew YEW; Chen WC; Chen YN; Chou CK
    Kaohsiung J Med Sci; 2023 Feb; 39(2):175-181. PubMed ID: 36448726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of recombinant human thyroid stimulating hormone on sustaining liver and renal function in thyroid cancer patients during radioactive iodine therapy.
    Lee SJ; Lee HY; Lee WW; Kim SE
    Nucl Med Commun; 2014 Jul; 35(7):727-32. PubMed ID: 24709982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosimetry of radioiodine therapy in patients with nodular goiter after pretreatment with a single, low dose of recombinant human thyroid-stimulating hormone.
    Nieuwlaat WA; Hermus AR; Ross HA; Buijs WC; Edelbroek MA; Bus JW; Corstens FH; Huysmans DA
    J Nucl Med; 2004 Apr; 45(4):626-33. PubMed ID: 15073259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.